[Comment] Expression of concern—Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Related Posts

• A Phase 3 Study on Serplulimab Plus Chemo for First-Line ES-SCLC

  KEY TAKEAWAYS A phase 3 trial evaluated the effectiveness and safety of serplulimab in combination…

• Targeting Molecular Alterations in Advanced Solid Tumors: My Pathway Study Phase 2A Study

  KEY TAKEAWAYS MyPathway is a phase IIa multiple basket trial assessing targeted agent activity for…

• Ribociclib Plus Fulvestrant Improves Survival in Postmenopausal Women With HR+/HER2− Advanced Breast Cancer

  KEY TAKEAWAYS The MONALEESA-3 phase III trial aimed to investigate the long-term OS benefits of…